



Drug Use Research & Management Program  
OHA Health Systems Division  
500 Summer Street NE, E35; Salem, OR 97301-1079  
Phone 503-947-5220 | Fax 503-947-1119

## Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, February 06, 2020 1:00 - 5:00 PM

DXC Conference Room

4070 27th Ct. SE

Salem, OR 97302

MEETING AGENDA

### MEETING MINUTES

---

**NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333**

**Members Present:** Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Tracy Klein, PHD, FNP; William Origer, MD, James Slater, PharmD; Patrick DeMartino, MD; Stacy Ramirez, PharmD; Cathy Zehrung RPh.

**Members Present by Phone:** Megan Herink, PharmD

**Staff Present:** Roger Citron, RPh; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Sara Fletcher, PharmD; Kathy Sentena, PharmD; Dee Weston; Trevor Douglass, DC, MPH; Brandon Wells; Jennifer Bowen;

**Audience:**

Will Lai, Xeris Pharmaceuticals\*; Jan Song, Xeris Pharmaceuticals; Anthony Mckenzie, OHSU; Suzanne Hensely, Xeris Pharmaceuticals; Kerri Miller, Blueprint Medicines; Ken Orr, Global Blood Therapeutics; Anthony Wheeler, Eli Lilly\*; Roy Lindfield Sunovion; Venus Holder, Eli Lilly; Doug Buriani, Sobi; BobbiJo Duim, BMS; Tracy Meeks, Vertex Pharmaceuticals; Garrett Funston, OHSU; Hiten Patadia, Otsuka; Rick Dabner, Alnylam Pharmaceuticals\*; Margaret Olmon, Abbvie\*; Samantha Shepard, CCO Oregon; Katie Scheelar, Moda; Lori McDermott, Supernus;

(\* ) Provided verbal testimony

**Written testimony provided:** Posted to OSU Website

---

I.

**CALL TO ORDER**

- A. The meeting was called to order at approximately 1:05 pm. Introductions were made by Committee members and staff
- B. Conflict of Interest Declaration - No new conflicts of interest were declared
- C. The Committee elected Jim Slater as the chair and Tracy Klein as the vice chair
- D. Approval of November 2019 minutes presented by Mr. Citron  
**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**
- E. Department and legislative update provided by Trevor Douglass

---

**II. OREGON ADMINISTRATIVE RULE CHANGES**

- A. Proposed Language for OAR 414-121-0111
- B. P&T Operating Procedures  
Ms. Weston presented the proposed amendments to OAR 414-121-0111

---

**III. CONSENT AGENDA TOPICS**

- A. P&T Methods for Quality Assessment of Evidence
- B. Immunosuppressants Literature Scan
- C. Diabetes, Insulins Literature Scan
- D. Jeuveau™ (prabotulinumtoxinA-xvfs) Abbreviated Drug Review
- E. Vyleesi™ (bremelanotide) Abbreviated Drug Review  
**Recommendation:**
  - 1. Make no changes to the preferred drug list (PDL) based on clinical evidence
  - 2. Designate prabotulinumtoxinA-xvfs and bremelanotide as not covered
  - 3. Evaluate comparative drug costs in executive session**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

**IV. DUR ACTIVITIES**

- A. Quarterly Utilization Reports – Mr. Citron presented the Utilization Report
- B. ProDUR Report - Mr. Holsapple presented the ProDUR report
- C. RetroDUR Report – Mr. Citron presented the RetroDUR Report
- D. Oregon State Drug Reviews
  - 1. Pearls and Pitfalls of Clinical Practice Guidelines
  - 2. Update on Recent Guidance and Safety Alerts for Opioid Use in Non-Cancer PainDr. Sentena presented two recently published newsletters, thanked the Committee for reviewing the draft versions and solicited ideas for future newsletters

---

## V. DUR NEW BUSINESS

### A. Orphan Drug Policy

Dr. Servid presented the policy proposal and proposed PA criteria

**ACTION:** The Committee recommended implementing the proposed PA criteria after amending to add a question requiring the medication be prescribed by or in consultation with an appropriate specialist for the condition to the initial approval criteria

**Motion to approve, 2<sup>nd</sup>, all in favor**

### B. Opioid Literature Scan and Prior Authorization Update

Dr. Servid presented the literature scan and proposed updates to the PA criteria for short- and long-acting opioids to prevent harm from abrupt discontinuation and reinforce a shared patient and provider decision for appropriate dosage reduction

**ACTION:** The Committee recommended implementing the proposed changes to the PA criteria after amending to remove the question requiring the provider to attest that the opioid will not be prescribed with a concurrent sedating medication

**Motion to approve, 2<sup>nd</sup>, all in favor**

### C. Febuxostat Prior Authorization Update

Dr. Sentena presented the proposal to add a requirement to the PA criteria that the patient has been assessed for CV risk and the benefits outweigh the risks.

**ACTION: Motion to reject, 2<sup>nd</sup>, 7 in favor, 1 opposed**

---

## III. PREFERRED DRUG LIST NEW BUSINESS

### A. Diabetes, Glucagon Class Review

Dr. Sentena presented the proposal to:

1. Create a PDL class for the glucagon products
2. Evaluate costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

### B. Xenleta™ (lefamulin) New Drug Evaluation

Dr. Herink presented the proposal to make oral lefamulin non-preferred in the miscellaneous antibiotic PDL class

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

C. Biologics for Autoimmune Conditions Class Update and New Drug Evaluations

Dr. Moretz presented the proposal to:

1. Update the PA criteria to reflect funding of treatment of moderate-to-severe hidradenitis suppurativa (HS) per Guideline Note 198 on the Prioritized List of Health Services
2. Modify the PA criteria to reflect updated indications and age ranges for specific biologic response modifiers
3. Evaluate comparative costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

D. Narcolepsy Agents Class Update with New Drug Evaluation

Dr. Servid presented the proposal to:

1. Update safety edits for narcolepsy drugs to incorporate modafinil, armodafinil, solriamfetol and pitolisant into a unified criterion
2. Evaluate comparative costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

## VI. EXECUTIVE SESSION

**Members Present:** Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Tracy Klein, PHD, FNP; William Origer, MD, James Slater, PharmD; Patrick DeMartino, MD; Stacy Ramirez, PharmD; Cathy Zehring RPh.

**Members Present by Phone:** Megan Herink, PharmD

**Staff Present:** Roger Citron, RPh; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Sarah Fletcher, PharmD; Kathy Sentena, PharmD; Dee Weston; Trevor Douglass, DC, MPH; Brandon Wells; Jennifer Bowen;

---

## VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Immunosuppressants Literature Scan

**Recommendation:** make all treatments preferred on the PMPDP

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

B. Diabetes, Insulins Literature Scan

**Recommendation:** make all forms of insulin lispro - except Admelog® - preferred on the PMPDP and to remove PA for insulin detemir pen

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

C. Diabetes, Glucagon Class Review

**Recommendation:** make GlucaGen®, glucagon emergency kit, and Baqsimi™ preferred and make Gvoke™ non-preferred on the PMPDP

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

D. Biologics for Autoimmune Conditions Class Update

**Recommendation:** make secukinumab preferred on the PMPDP

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

E. Narcolepsy Agents

**Recommendation:** make modafinil and armodafinil preferred on the PMPDP

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

**IX. ADJOURN**

---

**X. OHA Rules Advisory Committee**